330 related articles for article (PubMed ID: 22290600)
21. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.
Marinov M; Ziogas A; Pardo OE; Tan LT; Dhillon T; Mauri FA; Lane HA; Lemoine NR; Zangemeister-Wittke U; Seckl MJ; Arcaro A
Clin Cancer Res; 2009 Feb; 15(4):1277-87. PubMed ID: 19228731
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effects of ursolic acid in a mouse model of postmenopausal breast cancer.
De Angel RE; Smith SM; Glickman RD; Perkins SN; Hursting SD
Nutr Cancer; 2010; 62(8):1074-86. PubMed ID: 21058195
[TBL] [Abstract][Full Text] [Related]
23. Wnt-1 and int-2 mammary oncogene effects on the beta-catenin pathway in immortalized mouse mammary epithelial cells are not sufficient for tumorigenesis.
Hollmann CA; Kittrell FS; Medina D; Butel JS
Oncogene; 2001 Nov; 20(52):7645-57. PubMed ID: 11753642
[TBL] [Abstract][Full Text] [Related]
24. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
25. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
[TBL] [Abstract][Full Text] [Related]
26. FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.
Paul R; Luo M; Mo X; Lu J; Yeo SK; Guan JL
Breast Cancer Res; 2020 Jun; 22(1):59. PubMed ID: 32493400
[TBL] [Abstract][Full Text] [Related]
27. V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis.
Evert M; Calvisi DF; Evert K; De Murtas V; Gasparetti G; Mattu S; Destefanis G; Ladu S; Zimmermann A; Delogu S; Thiel S; Thiele A; Ribback S; Dombrowski F
Hepatology; 2012 May; 55(5):1473-84. PubMed ID: 22271091
[TBL] [Abstract][Full Text] [Related]
28. Omega-3-Acid Ethyl Esters Block the Protumorigenic Effects of Obesity in Mouse Models of Postmenopausal Basal-like and Claudin-Low Breast Cancer.
Ford NA; Rossi EL; Barnett K; Yang P; Bowers LW; Hidaka BH; Kimler BF; Carlson SE; Shureiqi I; deGraffenried LA; Fabian CJ; Hursting SD
Cancer Prev Res (Phila); 2015 Sep; 8(9):796-806. PubMed ID: 26100521
[TBL] [Abstract][Full Text] [Related]
29. Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001.
Yasui H; Naka N; Imura Y; Outani H; Kaneko K; Hamada K; Sasagawa S; Araki N; Ueda T; Itoh K; Myoui A; Yoshikawa H
Cancer Lett; 2014 May; 347(1):114-22. PubMed ID: 24491407
[TBL] [Abstract][Full Text] [Related]
30. Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development.
Wang X; Zhan Y; Zhao L; Alvarez J; Chaudhary I; Zhou BB; Abraham RT; Feuerstein GZ
J Pharmacol Exp Ther; 2011 Nov; 339(2):421-9. PubMed ID: 21835932
[TBL] [Abstract][Full Text] [Related]
31. GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity.
Maric G; Annis MG; MacDonald PA; Russo C; Perkins D; Siwak DR; Mills GB; Siegel PM
Oncogene; 2019 Jun; 38(26):5294-5307. PubMed ID: 30914799
[TBL] [Abstract][Full Text] [Related]
32. Rapamycin partially mimics the anticancer effects of calorie restriction in a murine model of pancreatic cancer.
Lashinger LM; Malone LM; Brown GW; Daniels EA; Goldberg JA; Otto G; Fischer SM; Hursting SD
Cancer Prev Res (Phila); 2011 Jul; 4(7):1041-51. PubMed ID: 21593197
[TBL] [Abstract][Full Text] [Related]
33. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma.
Imura Y; Yasui H; Outani H; Wakamatsu T; Hamada K; Nakai T; Yamada S; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
Mol Cancer; 2014 Aug; 13():185. PubMed ID: 25098767
[TBL] [Abstract][Full Text] [Related]
34. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
35. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
Grozinsky-Glasberg S; Franchi G; Teng M; Leontiou CA; Ribeiro de Oliveira A; Dalino P; Salahuddin N; Korbonits M; Grossman AB
Neuroendocrinology; 2008; 87(3):168-81. PubMed ID: 18025810
[TBL] [Abstract][Full Text] [Related]
36. Mammary tumor regression elicited by Wnt signaling inhibitor requires IGFBP5.
Liu BY; Soloviev I; Huang X; Chang P; Ernst JA; Polakis P; Sakanaka C
Cancer Res; 2012 Mar; 72(6):1568-78. PubMed ID: 22307840
[TBL] [Abstract][Full Text] [Related]
37. Diet-induced obesity and mammary tumor development in MMTV-neu female mice.
Cleary MP; Grande JP; Juneja SC; Maihle NJ
Nutr Cancer; 2004; 50(2):174-80. PubMed ID: 15623464
[TBL] [Abstract][Full Text] [Related]
38. Decreased systemic IGF-1 in response to calorie restriction modulates murine tumor cell growth, nuclear factor-κB activation, and inflammation-related gene expression.
Harvey AE; Lashinger LM; Otto G; Nunez NP; Hursting SD
Mol Carcinog; 2013 Dec; 52(12):997-1006. PubMed ID: 22778026
[TBL] [Abstract][Full Text] [Related]
39. Estrogen inhibits the effects of obesity and alcohol on mammary tumors and fatty liver.
Hong J; Holcomb VB; Kushiro K; Núñez NP
Int J Oncol; 2011 Dec; 39(6):1443-53. PubMed ID: 21850368
[TBL] [Abstract][Full Text] [Related]
40. Dose-dependent effects of calorie restriction on gene expression, metabolism, and tumor progression are partially mediated by insulin-like growth factor-1.
Nogueira LM; Lavigne JA; Chandramouli GV; Lui H; Barrett JC; Hursting SD
Cancer Med; 2012 Oct; 1(2):275-88. PubMed ID: 23342276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
